Telix Pharmaceuticals announced the appointments of Mr Kevin McCann AM and Dr Mark Nelson to its Board of Directors.
Mr McCann, who is Chairman of Citadel Group, Dixon Hospitality and the Sydney Harbour Federation Trust, will serve as Chairman.
He is a former Chairman of Macquarie Group and Macquarie Bank, Origin Energy, Healthscope and ING Management. He practiced as a commercial lawyer as a Partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004.
Dr Nelson is Chairman and co-founder of the Caledonia Investments Group and a Director of The Caledonia Foundation.
He is vice president of the Board of Trustees of the Art Gallery of New South Wales, deputy chairman of Art Exhibitions Australia, a Director of Kaldor Public Art Projects and serves as a governor of the Florey Neurosciences Institute.
According to Telix co-founder and CEO, Christian Behrenbruch, “We are very pleased to have Kevin and Mark join the Telix board at this important time in the Company’s development. They bring a tremendous amount of experience and perspective in capital markets, corporate governance and commercial strategy.”
Founding Directors Mr Michael Cawley and Dr Richard Zimmermann will step down from their roles as non-executive directors. Dr Zimmermann will remain an adviser to the company.
Telix is an Australian-based company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation.